Goz B, Bastow K F
Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill 27599, USA. gozbpg@med unc.edu
Mutat Res. 1997 Aug;384(2):89-106. doi: 10.1016/s0921-8777(97)00016-5.
Pretreatment of cells with AraC markedly enhances the frequency of resistance to PALA, methotrexate and 5-fluoro-2'-deoxyuridine (FdUrd) (D.V. De Cicco, A.C. Spradling, Localization of a cis-acting element responsible for the developmentally regulated amplification of Drosophila chorion genes. Cell 38 (1984) 45-54). As a part of studies to elucidate the mechanism for this effect of AraC, the SV40 transformed baby hamster kidney cell line SV28 was treated with either AraC, etoposide or etoposide plus verapamil (to avoid selection for P-glycoprotein-mediated resistance) to isolate cells resistant to AraC or etoposide, respectively. The cells isolated for resistance to AraC (500) were cross-resistant to etoposide and the cells isolated for resistance to etoposide (V5ER and 20ER) were cross-resistant to AraC as well as FdUrd (only V5ER were tested). Enhancement of PALA-resistance frequency by pretreatment with various AraC concentrations and exposure times was greatly attenuated in the three resistant cell lines. Pretreatment with FdUrd markedly enhanced PALA-resistance frequency in SV28 cells, but only weakly did so in V5ER cells. All three resistant cell lines had diminished topoisomerase II as measured by immunoblotting and which was reflected in increased LC50s for etoposide. A comparison of either the etoposide LC50 values or the amount of cellular topoisomerase II, as measured by immunoblotting, with the PALA-resistance frequency in the SV28 and resistant cell lines showed a clear correlation. Increased etoposide LC50 or decreased topoisomerase II correlate with increased PALA-resistance frequency. This holds true for cells treated or not pretreated with AraC. Cells with reduced topoisomerase II are more resistant to the lethal actions of not only etoposide, but also AraC and FdUrd, drugs with different primary sites of action. Cells with reduced topoisomerase II have a higher frequency of resistance to PALA by gene amplification and reduced enhancement of gene amplification frequency when treated with AraC or FdUrd. This suggests two different mechanisms responsible for the increased frequency of resistance and the reduced enhancement of resistance frequency, respectively. These data suggest a role for topoisomerase II in cell death and gene amplification. Possible mechanisms are discussed and a scheme is presented.
用阿糖胞苷(AraC)对细胞进行预处理可显著提高对N-磷酸乙酰-L-天冬氨酸(PALA)、甲氨蝶呤和5-氟-2'-脱氧尿苷(FdUrd)的耐药频率(D.V. 德西科,A.C. 斯普拉德林,负责果蝇绒毛膜基因发育调控扩增的顺式作用元件的定位。《细胞》38卷(1984年)45 - 54页)。作为阐明AraC这种作用机制研究的一部分,用AraC、依托泊苷或依托泊苷加维拉帕米(以避免选择P-糖蛋白介导的耐药性)处理SV40转化的幼仓鼠肾细胞系SV28,以分别分离出对AraC或依托泊苷耐药的细胞。分离出的对AraC耐药的细胞(500)对依托泊苷也有交叉耐药性,而分离出的对依托泊苷耐药的细胞(V5ER和20ER)对AraC以及FdUrd也有交叉耐药性(仅对V5ER进行了测试)。在这三种耐药细胞系中,用不同浓度AraC和不同暴露时间进行预处理对PALA耐药频率的增强作用大大减弱。用FdUrd预处理可显著提高SV28细胞中PALA的耐药频率,但在V5ER细胞中作用较弱。通过免疫印迹法检测,所有三种耐药细胞系的拓扑异构酶II含量均降低,这反映在依托泊苷的半数致死浓度(LC50)升高。通过免疫印迹法测量的依托泊苷LC50值或细胞拓扑异构酶II的量与SV28细胞系及耐药细胞系中PALA耐药频率的比较显示出明显的相关性。依托泊苷LC50升高或拓扑异构酶II减少与PALA耐药频率增加相关。这对于用或未用AraC预处理的细胞均成立。拓扑异构酶II含量降低的细胞不仅对依托泊苷的致死作用更具耐药性,而且对AraC和FdUrd也更具耐药性,这两种药物的主要作用位点不同。拓扑异构酶II含量降低的细胞通过基因扩增对PALA具有更高的耐药频率,并且在用AraC或FdUrd处理时基因扩增频率的增强作用减弱。这表明分别存在两种不同的机制导致耐药频率增加和耐药频率增强作用减弱。这些数据表明拓扑异构酶II在细胞死亡和基因扩增中起作用。讨论了可能的机制并给出了一个示意图。